[go: up one dir, main page]

EA201691555A1 - Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени - Google Patents

Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени

Info

Publication number
EA201691555A1
EA201691555A1 EA201691555A EA201691555A EA201691555A1 EA 201691555 A1 EA201691555 A1 EA 201691555A1 EA 201691555 A EA201691555 A EA 201691555A EA 201691555 A EA201691555 A EA 201691555A EA 201691555 A1 EA201691555 A1 EA 201691555A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
dystrophies
liver
fatial
prevention
Prior art date
Application number
EA201691555A
Other languages
English (en)
Inventor
Кейт С. Усискин
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52544570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201691555(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201691555A1 publication Critical patent/EA201691555A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способам лечения, задержки, замедления прогрессирования и/или предотвращения расстройств, включающим введение нуждающемуся в этом субъекту терапевтически эффективного количества комбинированного терапевтического средства, содержащего, состоящего из или состоящего по существу из: (а) канаглифлозина и (b) одного или более ингибиторов АСЕ, или одного или более ARB, или одного или более агонистов PPAR-гамма; и к способам лечения, задержки, замедления прогрессирования и/или предотвращения жировых дистрофий печени (например, NASH или NAFLD), включающим введение нуждающемуся в этом субъекту терапевтически эффективного количества канаглифлозина.
EA201691555A 2014-01-31 2015-01-30 Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени EA201691555A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461934003P 2014-01-31 2014-01-31
US201461948882P 2014-03-06 2014-03-06
PCT/US2015/013644 WO2015116880A1 (en) 2014-01-31 2015-01-30 Methods for the treatment and prevention of renal disorders and fatty liver disorders

Publications (1)

Publication Number Publication Date
EA201691555A1 true EA201691555A1 (ru) 2017-01-30

Family

ID=52544570

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691555A EA201691555A1 (ru) 2014-01-31 2015-01-30 Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени

Country Status (11)

Country Link
US (3) US20160339047A1 (ru)
EP (1) EP3099328A1 (ru)
JP (2) JP2017504649A (ru)
KR (1) KR20160107344A (ru)
CN (3) CN105939728A (ru)
AU (2) AU2015210898A1 (ru)
CA (1) CA2938406A1 (ru)
EA (1) EA201691555A1 (ru)
IL (1) IL246779A0 (ru)
MX (1) MX2016010011A (ru)
WO (1) WO2015116880A1 (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018532720A (ja) * 2015-09-16 2018-11-08 トビラ セラピューティクス， インコーポレイテッド 線維症の治療のためのセニクリビロック併用療法
DK3370776T3 (da) * 2015-11-06 2024-06-17 Gelteq Ltd Fremgangsmåde og produkt til test af respons på oral glucosedosis
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
TWI835735B (zh) * 2017-06-12 2024-03-21 比利時商健生藥品公司 減少或預防第ii型糖尿病患者中心血管事件之方法
CN109806397A (zh) * 2017-11-20 2019-05-28 江苏恒瑞医药股份有限公司 Sglt2抑制剂与arb联合在制备治疗高血压等疾病的药物中的用途
EA202091324A1 (ru) 2017-11-30 2020-10-05 Идорсия Фармасьютиклз Лтд Комбинация 4-пиримидинсульфамидного производного с ингибитором sglt-2 для лечения заболеваний, связанных с эндотелином
TW202103709A (zh) * 2019-03-26 2021-02-01 比利時商健生藥品公司 用於治療患有慢性腎臟病之對象的方法
CN110051851A (zh) * 2019-05-31 2019-07-26 江苏苏中药业集团股份有限公司 一种钠-葡萄糖共转运蛋白-2抑制剂与黄蜀葵花提取物的组合
KR20230057388A (ko) * 2020-08-17 2023-04-28 티엔진 크레아트론 바이오테크놀로지 컴파니 리미티드 Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
WO2022104621A1 (zh) * 2020-11-19 2022-05-27 北京睿创康泰医药研究院有限公司 固定剂量的sglt-2抑制剂与血管紧张素转化酶抑制剂的组合物及用途
JP2024094532A (ja) 2022-12-28 2024-07-10 キヤノン株式会社 撮像設定装置および撮像装置
KR20240126452A (ko) * 2023-02-10 2024-08-21 가천대학교 산학협력단 칸데사르탄 또는 아질사르탄을 포함하는 조성물의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK133897A3 (en) * 1995-04-07 1998-02-04 Ciba Geigy Ag Combination compositions containing benazepril or benazeprilat and valsartan
JP4130466B2 (ja) 2003-08-01 2008-08-06 田辺三菱製薬株式会社 新規化合物
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008113095A1 (en) * 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
UY32030A (es) * 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
JP6250280B2 (ja) * 2009-03-26 2017-12-20 グプタ，アジャイ 腎疾患の治療のための組成物及び方法
JP2013523681A (ja) * 2010-03-30 2013-06-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２インヒビター及びｐｐａｒ−ガンマアゴニストを含む医薬組成物並びにその使用
JP5889321B2 (ja) * 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のｉｂａｔ阻害剤
MX2013005242A (es) * 2010-11-11 2013-06-12 Redx Pharma Ltd Derivados de farmacos.
AR083878A1 (es) * 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento

Also Published As

Publication number Publication date
CN113082021A (zh) 2021-07-09
CA2938406A1 (en) 2015-08-06
IL246779A0 (en) 2016-08-31
KR20160107344A (ko) 2016-09-13
AU2020281039A1 (en) 2021-01-07
EP3099328A1 (en) 2016-12-07
US20160339047A1 (en) 2016-11-24
CN113144204A (zh) 2021-07-23
JP2017504649A (ja) 2017-02-09
JP2020090511A (ja) 2020-06-11
MX2016010011A (es) 2016-10-07
US20210121492A1 (en) 2021-04-29
AU2015210898A1 (en) 2016-07-28
WO2015116880A1 (en) 2015-08-06
CN105939728A (zh) 2016-09-14
US20180344756A1 (en) 2018-12-06

Similar Documents

Publication Publication Date Title
EA201691555A1 (ru) Способы лечения и предотвращения заболеваний почек и жировых дистрофий печени
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
EA201790398A1 (ru) Способы лечения заболевания печени
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
MX2024010140A (es) Nuevos metodos.
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
WO2015103438A3 (en) Oncolytic virus adjunct therapy with agents that increase virus infectivity
EA201690212A1 (ru) Способы лечения или профилактики офтальмологических патологических состояний
EA201691481A1 (ru) ИНГИБИТОРЫ C5a ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ПНЕВМОНИИ
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
TW201613578A (en) Pharmaceutical combinations
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
EA201791933A1 (ru) Ингибирование активности olig2
EA201892297A1 (ru) Способы лечения холестатических и фибротических заболеваний
EA201990508A1 (ru) ИНГИБИРОВАНИЕ АКТИВНОСТИ Olig2
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares